FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.
Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients.
Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023